Adelaide Research & Scholarship: Search

Search

Results 1-7 of 7 (Search time: 0.003 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2023	A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data	Sharplin, K.; Proudman, W.; Chhetri, R.; Tran, E.N.H.; Choong, J.; Kutyna, M.; Selby, P.; Sapio, A.; Friel, O.; Khanna, S.; Singhal, D.; Damin, M.; Ross, D.; Yeung, D.; Thomas, D.; Kok, C.H.; Hiwase, D.
	2023	Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention	Shanmuganathan, N.; Wadham, C.; Shahrin, N.; Feng, J.; Thomson, D.; Wang, P.; Saunders, V.; Kok, C.H.; King, R.M.; Kenyon, R.R.; Lin, M.; Pagani, I.S.; Ross, D.M.; Yong, A.S.M.; Grigg, A.P.; Mills, A.K.; Schwarer, A.P.; Braley, J.; Altamura, H.; Yeung, D.T.; et al.
	2023	Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	Kok, C.H.; Saunders, V.A.; Dang, P.; Shanmuganathan, N.; White, D.; Branford, S.; Yeung, D.; Hughes, T.P.
	2023	Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia	Irani, Y.D.; Kok, C.H.; Clarson, J.; Shanmuganathan, N.; Branford, S.; Yeung, D.T.; Ross, D.M.; Hughes, T.P.; Yong, A.S.
	2023	Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.	Baranwal, A.; Chhetri, R.; Yeung, D.; Clark, M.; Shah, S.; Litzow, M.R.; Hogan, W.J.; Mangaonkar, A.; Alkhateeb, H.B.; Singhal, D.; Cibich, A.; Bardy, P.; Kok, C.H.; Hiwase, D.K.; Shah, M.V.
	2023	Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes.	Montarello, N.; Leslie, A.; Chhetri, R.; Friel, O.; Singhal, D.; Ross, D.M.; Yeung, D.T.; Kok, C.H.; Psaltis, P.J.; Hiwase, D.K.
	2023	The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism	Leow, B.C.S.; Kok, C.H.; Yeung, D.T.; Hughes, T.P.; White, D.L.; Eadie, L.N.